Visit with us at SOT in Baltimore!
We look forward to seeing you at SOT in Baltimore for a week of scientific discussion. Representing Alturas Analytics are Robin Woods, President and Ann Hoffman, Director of Business Development. Contact Ann Hoffman via email to arrange a time and place to discuss advancements in bioanalysis that help bring drugs to market faster and safer. The MS/MS Experts.
Strong Science, Intelligent Decisions, Faster Results: Delivery of SEND-compliant datasets on time with the highest level of integrity is our greatest priority. Alturas Analytics scientists are known as leaders for developing and validating robust MS/MS methods rapidly, across a broad range of compounds in many biological matrices. We support drug candidates from discovery through phase IV clinical trials.
Microsampling: In recent months the industry has experienced a resurgence of innovative developments in microsampling as a viable alternative to standard blood draws. Together with the enhanced performance of analytical instruments, a single drop of blood can produce the precision and accuracy to meet regulatory standards. Alturas Analytics is a known pioneer of dried matrix spot bioanalytical methods and an active contributor in applying new microsampling techniques such as plasma extraction cards and calibrated capillary sampling to routine sample analysis.
Go to The Evaluation of Noviplex Plasma Prep Cards for Regulated Bioanalysis.
Personalized Service: We measure the success of the company by the loyalty of our clients. Fostering strong and lasting relationships with our sponsors, while retaining the flexibility needed to accommodate the unique needs of every project is a core value at Alturas Analytics. From our scientific operations to our quality assurance unit (QAU), the Alturas staff has the skills and experience to adapt to changing timelines and rapid turnarounds.
Looking Forward to 2017 and Beyond
A Message From Robin Woods, President
At Alturas Analytics, 2016 was the year for building infrastructure and preparing for growth to meet new challenges. With investments in capital equipment, scientific staff, a facility expansion, and company-wide software upgrade and integration, we enter 2017 with greater capacity and streamlined processes operated by an enhanced team of talented professionals.
The Year Ahead
With gains in sensitivity from a wide variety of analytical platforms in combination with the specificity of immunoaffinity capture, we anticipate an increase in the migration of large molecule quantitation to LC-MS/MS from traditional techniques. Alturas is engaged in a focused effort in this area to provide fully validated assays for biologics, whether protein and peptide therapeutics, biomarkers, antibody-drug conjugates (ADC) or RNA drugs to address the non-specificity and often lengthy development cycles of ligand binding assays. Routine LC-MS/MS bioanalysis of large molecules performed in a regulated environment is a great complement to our lengthy history and extensive experience with ADCs. With our scientific expertise and the loyalty of our ADC clients, this presents major growth potential for Alturas.
As a pioneer of dried matrix spot analytical procedures, we are encouraged with the resurgence of innovative developments in microsampling techniques as a viable alternative to standard blood draws. Collection cards, capillaries, swabs or other microsampling techniques are ideal when sample volume is limited such as with preclinical models, tears, support of pediatric studies or collecting samples in remote regions where centrifuges and freezers are scarce or nonexistent. Alturas remains an active contributor in the realm of microsampling techniques and we are currently working towards the use of NoviplexTM plasma extraction cards in support of regulated bioanalysis. Unlike dried blood spot cards, plasma is extracted from a single blood drop so hematocrit effects do not exist, samples are more stable, and data is comparable with methods that use conventional plasma collection procedures. Microsampling is already embedded into routine preclinical workflows in the research environment.
Alturas has much to look forward to in 2017 and beyond with enhanced, streamlined operations and a deepened portfolio. Our timeline driven service strategy provides the culture for controlled growth and stability to succeed in a progressive industry that is constantly pressing the limits
The future looks bright and we are ready for the challenge. Wishing you all success in the new year!